Trial Profile
A Phase I/II Trial to Assess Safety and Tolerability of an Oral Aurora Kinase A Inhibitor, MLN8237, In Combination With Erlotinib In Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 23 May 2018
Price :
$35
*
At a glance
- Drugs Alisertib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 14 May 2018 Status changed to discontinued as Phase I portion completed. Phase II will open pending amendment approval.
- 08 Sep 2017 Planned End Date changed from 31 Jul 2018 to 31 Jul 2019.
- 08 Sep 2017 Planned primary completion date changed from 27 Aug 2017 to 27 Aug 2018.